Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Insulet (PODD)
NASDAQ:PODD
Holding PODD?
Track your performance easily
PODD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$160.19 - $279.77
Previous Close$269.34
Volume551.50K
Average Volume (3M)556.80K
Market Cap
$18.89B
Enterprise Value$19.39B
Total Cash (Recent Filing)$902.60M
Total Debt (Recent Filing)$1.40B
Price to Earnings (P/E)45.8
Beta1.32
Next Earnings
Feb 20, 2025EPS Estimate
$1.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.88
Shares Outstanding70,144,775
10 Day Avg. Volume578,650
30 Day Avg. Volume556,805
Standard Deviation0.12
R-Squared0.30
Alpha-0.00238
Financial Highlights & Ratios
Price to Book (P/B)16.90
Price to Sales (P/S)9.52
Price to Cash Flow (P/CF)48.00
P/FCF Ratio68.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.77
Enterprise Value/Gross Profit16.72
Enterprise Value/Ebitda73.36
Forecast
1Y Price Target
$288.93Price Target Upside8.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Insulet News
PremiumCompany Announcements
Insulet Reports Strong Revenue Growth and Optimistic OutlookBulls Say, Bears Say
Bulls Say
Legal VictoryThe U.S. district court delivered a jury trial verdict in favor of PODD against EOFlow, with a total of $452M in damages awarded to PODD for trade secret misappropriation.
Market ExpansionThe outlook for type 2 diabetes market expansion is encouraging, with management confident in reaching a significant portion of US patients.
Product IntegrationOmnipod 5 being compatible with Abbott’s leading CGM, FreeStyle Libre 2 Plus, is an incremental positive for Insulet.
Bears Say
Competitive PressureCompetitor T2 pump approvals are expected to follow, which could lead to competitive pressure in the T2 segment.
Financial UncertaintyEOFlow's ability to satisfy the damage award is not known with certainty.
Revenue Growth ConcernsThe updated guidance was seen as a soft spot as it suggests US Omnipod revenue growth below Q4 consensus expectations.
---
Ownership Overview
0.36% Insiders
40.94% Mutual Funds
32.60% Other Institutional Investors
0.67% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PODD FAQ
What was Insulet’s price range in the past 12 months?
Insulet lowest stock price was $160.19 and its highest was $279.77 in the past 12 months.
What is Insulet’s market cap?
Currently, no data Available
When is Insulet’s upcoming earnings report date?
Insulet’s upcoming earnings report date is Feb 20, 2025 which is in 61 days.
How were Insulet’s earnings last quarter?
Insulet released its earnings results on Nov 07, 2024. The company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.778 by $0.302.
Is Insulet overvalued?
According to Wall Street analysts Insulet’s price is currently Undervalued.
Does Insulet pay dividends?
Insulet does not currently pay dividends.
What is Insulet’s EPS estimate?
Insulet’s EPS estimate is $1.03.
How many shares outstanding does Insulet have?
Insulet has 70,144,775 shares outstanding.
What happened to Insulet’s price movement after its last earnings report?
Insulet reported an EPS of $1.08 in its last earnings report, beating expectations of $0.778. Following the earnings report the stock price went up 9.397%.
Which hedge fund is a major shareholder of Insulet?
Among the largest hedge funds holding Insulet’s share is PRIMECAP Management Co. It holds Insulet’s shares valued at 129M.
---
Insulet Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$288.93 (8.82% Upside)
$288.93 (8.82% Upside)
Blogger Sentiment
Bullish
PODD Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 325.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $139.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.4%
Last 30 Days ▲ 8.4%
Last 30 Days ▲ 8.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.49%
12-Months-Change
Fundamentals
Return on Equity
48.79%
Trailing 12-Months
Asset Growth
22.60%
Trailing 12-Months
Company Description
Insulet
Insulet Corp. is a medical device company. The firm engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
---
PODD Company Deck
---
PODD Earnings Call
Q3 2024
0:00 / 0:00
---
PODD Revenue Breakdown
73.71% U.S. Omnipod
24.16% International Omnipod
2.12% Drug Delivery
---
PODD Stock 12 Month Forecast
Average Price Target
$288.93
▲(8.82% Upside)
Technical Analysis
Best Analysts Covering PODD
1 Year
1 Year Success Rate
16/18 ratings generated profit
1 Year Average Return
+28.88%
assigned a buy rating 10 days ago
Copying Larry Biegelsen's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +28.88% per trade.
---